Close

Torrent Pharma acquires 4 Brands from Dr.Reddy’s laboratories

Related stories

hubXchange Announces Upcoming Series of Exclusive Roundtable Events in San Diego – February 2025

hubXchange, the premier platform for senior-level knowledge exchange in...

Aragen receives Platinum Medal from EcoVadis for its sustainability initiatives

Hyderabad: Aragen Life Sciences, a globally renowned Contract Research,...

Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report

Paris: New research released ahead of Pharmapack Europe – the continent’s largest...

Danish protein analysis to revolutionize the biopharma industry’s impurity control

The requirements for quality assurance of biologics are increasing....

Berry Global Healthcare to Showcase New Packaging Innovations at Pharmapack 2025

Berry Global Healthcare, a leader in innovative packaging solutions,...

Ahmedabad based Torrent Pharmaceuticals  announced that it has entered into an agreement with Dr. Reddy’s Laboratories Ltd. to acquire four of its brands “Styptovit-E”, “Finast”, “Finast-T”, and “Dynapress”.

Styptovit-E, a gynaecology product with an estimated market size of ~Rs. 500 crores (AIOCD data set), will further strengthen Torrent’s presence in the therapy. The acquisition of “Finast”, “Finast-T”, and “Dynapress”, which are used in the treatment of Benign Prostatic Hyperplasia (BPH), will aid in Torrent’s presence in the Urology therapy.

As per the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India. The complete integration and transition of the brands are expected to be completed by June 2022.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories